Avastin (Bevacizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The avastin (bevacizumab) market size has grown strongly in recent years. It will grow from $7.82 million in 2025 to $8.43 million in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to clinical validation of vegf inhibition, rising global cancer burden, broad label expansion approvals, strong oncologist familiarity, early adoption in colorectal cancer.

The avastin (bevacizumab) market size is expected to see strong growth in the next few years. It will grow to $11.27 million in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growth of bevacizumab biosimilars, expanding oncology patient pool, increased use in emerging markets, demand for cost effective biologics, combination regimen optimization. Major trends in the forecast period include continued use of anti-angiogenic cancer therapies, expansion of avastin use across multiple cancer types, growing combination therapy with chemotherapy, rising adoption in ophthalmic indications, increased focus on biosimilar competition.

The increasing prevalence of cancer is expected to drive the growth of the Avastin (bevacizumab) market going forward. Cancer is a collective term for diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rising prevalence of cancer is attributed to factors such as aging populations, lifestyle changes, and advances in diagnostic and screening methods. Avastin treats cancer by inhibiting vascular endothelial growth factor (VEGF), thereby preventing the formation of blood vessels that supply tumors with oxygen and nutrients, effectively restricting tumor growth. For instance, in August 2024, according to Macmillan Cancer Support, a UK-based organization, more than 3 million people in the UK were living with cancer in 2024, and this number is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the growing prevalence of cancer is driving the expansion of the Avastin (bevacizumab) market.

Rising healthcare expenditure is expected to further propel the growth of the Avastin (bevacizumab) market going forward. Healthcare expenditure refers to total spending on healthcare goods and services, including personal medical care, preventive services, and public health initiatives, aimed at improving health outcomes over a given period. Increased healthcare spending is driven by factors such as an aging population, a higher burden of chronic diseases, advances in medical technology, elevated drug costs, inefficient payment systems, and growing demand for healthcare services. Higher healthcare expenditure supports the use of Avastin by improving insurance coverage and patient access, thereby contributing to market growth. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is driving the Avastin (bevacizumab) market.

Major companies operating in the Avastin (bevacizumab) market are increasingly emphasizing biosimilar proliferation, including the launch of high-profile bevacizumab biosimilars, to strengthen their competitive positioning. Biosimilar proliferation refers to the rapid growth in the availability and adoption of biosimilar products within the market. For instance, in December 2023, Bio-Thera Solutions, a China-based biopharmaceutical company, received FDA approval for Avzivi (bevacizumab-tnjn), a biosimilar to Avastin that demonstrated comparable efficacy, safety, and immunogenicity to the reference product. In July 2024, the European Medicines Agency (EMA) also approved BAT1706/Avzivi for multiple oncology indications. These approvals are improving affordability and expanding patient access, while also increasing pricing pressure on the originator product, intensifying competition, and raising manufacturing and supply challenges for market participants.

Major companies operating in the avastin (bevacizumab) market are Roche Holding AG.

North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the avastin (bevacizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the avastin market by increasing costs associated with monoclonal antibody production inputs, sterile vial packaging, and cold-chain logistics. These impacts are more pronounced in import-dependent regions such as asia pacific and parts of eastern europe. Hospital and tender-based distribution channels face pricing pressures due to higher landed costs. At the same time, tariffs have accelerated investments in local biologics manufacturing and biosimilar production. This supports competitive pricing and strengthens regional oncology supply chains.

The avastin (bevacizumab) market research report is one of a series of new reports that provides avastin (bevacizumab) market statistics, including avastin (bevacizumab) industry global market size, regional shares, competitors with a avastin (bevacizumab) market share, detailed avastin (bevacizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the avastin (bevacizumab) industry. This avastin (bevacizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and inhibits angiogenesis, the process by which new blood vessels form to supply tumors with oxygen and nutrients. It is commonly used in combination with chemotherapy to treat several types of cancer, including colorectal, lung, kidney, and glioblastoma.

The primary dosage strengths of Avastin (bevacizumab) are 100 mg and 400 mg. The 100 mg dose is used in the treatment of various cancers by preventing the development of blood vessels that support tumor growth. Its applications include non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, and others. These products are distributed through channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by end users including hospitals, cancer supportive care centers, home healthcare settings, academic and research institutes, and others.

The avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.